LB Pharmaceuticals Sets Oct. 27 R&D Day Ahead of Phase 3 Data
LB Pharmaceuticals will hold an in-person and virtual R&D Day on Oct. 27, spotlighting its LB-102 schizophrenia drug ahead of Phase 3 topline results.
LB Pharmaceuticals Inc (Nasdaq: LBRX) announced Tuesday it will host a combined in-person and virtual R&D Day on October 27, 2026, with presentations starting at 2:00 PM ET and a reception to follow. The New York-based neuromedicines company is staging the event as it prepares for an anticipated topline data readout from its Phase 3 clinical trial of LB-102 in schizophrenia.
The event will feature University of Toronto psychiatrist Roger S. McIntyre, MD, FRCPC, a prominent researcher in the field of brain disorders, appearing alongside the company's senior leadership. Chief Executive Officer Heather Turner, Chief Medical Officer Susan G. Kozauer, Chief Commercial Officer Kaya Pai Panandiker, Chief Operating and Business Officer Gad Soffer, and Chief Financial Officer Joe Miller are all scheduled to present.
Read more Rocky Mountain Chocolate Factory Sells Durango HQ for $6.6M in Related-Party Deal →
LB Pharmaceuticals describes itself as focused on developing therapies that address what it calls the multiple dimensions of underserved brain disorders. The R&D Day represents an opportunity for investors and analysts to assess the company's clinical strategy and commercial readiness before pivotal trial results are disclosed.
Schizophrenia remains a condition with significant unmet medical need, and Phase 3 readouts in the space draw close scrutiny from the broader psychiatric drug development community. The timing of the event, just weeks after its announcement, signals the company expects its data milestone to be imminent.
Registration details are available through the company's official announcement. Continue reading at GlobeNewswire - Industry News on Financial Services.
